Seres therapeutics, inc. (MCRB)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Sep'14Jun'14
Revenue:
Collaboration revenue - related party

5,462

5,279

4,840

10,454

6,615

10,196

8,684

4,271

3,766

-

-

3,014

-

-

-

-

-

-

-

-

-

-

-

Grant revenue

739

311

85

260

446

433

371

341

205

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue

1,988

2,032

2,106

1,817

260

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue - related party

-

-

-

-

-

-

-

-

-

-

-

-

3,015

-

13,015

3,004

2,710

-

-

-

-

-

-

Total revenue

8,189

7,622

7,031

12,531

7,321

10,629

9,055

4,612

3,971

-

23,015

-

3,015

3,037

13,015

3,004

2,710

-

-

0

-

0

0

Operating expenses:
Research and development expenses

21,743

21,032

18,317

17,905

22,887

24,767

23,675

24,053

23,460

24,042

22,210

23,060

20,143

20,256

24,143

22,174

15,416

10,677

9,850

8,784

8,784

2,466

2,160

General and administrative expenses

6,138

5,782

5,897

5,574

7,495

7,533

7,591

8,695

8,777

8,789

8,119

8,370

8,762

8,469

7,967

8,970

7,210

4,938

4,711

3,556

3,556

1,113

458

Restructuring expenses

0

0

0

0

1,492

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

27,881

26,814

24,214

23,479

31,874

32,300

31,266

32,748

32,237

32,831

30,329

31,430

28,905

28,725

32,110

31,144

22,626

15,615

14,561

12,340

12,340

3,579

2,618

Loss from operations

-19,692

-19,192

-17,183

-10,948

-24,553

-21,671

-22,211

-28,136

-28,266

-29,775

-7,314

-28,416

-25,890

-25,688

-19,095

-28,140

-19,916

-15,615

-14,561

-12,340

-12,340

-3,579

-2,618

Other income (expense):
Interest income

159

-

-

-

220

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

716

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income (expense), net

-

-

335

189

-

-

262

349

347

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

615

-

-

719

495

268

-

172

48

151

-

-

Other income (expense)

-

-

-

-

-

-

-

-

-

-

-

-217

-

-

-312

-268

-56

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

231

65

146

-

-

Interest income (expense), net

-

-

-

-

-

-

-

-

-

-

379

-

416

-

-

-

-

-

-

5

-

-61

-56

Other income

368

-

439

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revaluation of preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

433

-220

-220

-521

-3

Total other income (expense), net

-189

414

774

189

220

384

262

349

347

822

379

398

416

414

407

227

212

565

-59

-215

-215

-582

-59

Net loss

-19,881

-18,778

-16,409

-10,759

-24,333

-21,287

-21,949

-27,787

-27,919

-28,953

-6,935

-28,018

-25,474

-25,274

-18,688

-27,913

-19,704

-15,050

-14,620

-12,555

-12,555

-4,161

-2,677

Accretion of convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

461

325

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-12,555

-

-4,622

-3,002

Net loss per share attributable to common stockholders, basic and diluted

-0.28

-0.18

-0.23

-0.24

-0.59

-0.52

-0.54

-0.68

-0.69

-0.72

-0.17

-0.69

-0.63

-0.64

-0.46

-0.70

-0.50

0.95

-0.38

-1.45

-1.45

-0.68

-0.45

Weighted average common shares outstanding, basic and diluted

70,821

70,484

69,944

45,140

41,027

40,877

40,806

40,661

40,628

40,540

40,494

40,394

40,368

40,365

40,235

39,600

39,186

37,868

38,980

8,640

8,640

6,767

6,725

Net loss

-19,881

-18,778

-16,409

-10,759

-24,333

-21,287

-21,949

-27,787

-27,919

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other comprehensive loss:
Unrealized loss on investments, net of tax of $0

-10

-

7

-

-

9

20

77

40

-47

77

-25

-2

-82

-150

-25

78

79

-33

-8

-8

-

-

Total other comprehensive loss

-10

-

7

-

-

9

20

77

40

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other comprehensive income

-

-

-

-

-

-

-

-

-

-

77

-25

-2

-

-150

-25

78

79

-33

-8

-8

-

-

Comprehensive loss

-19,891

-18,785

-16,402

-10,759

-24,333

-21,278

-21,929

-27,710

-27,879

-29,000

-6,858

-28,043

-25,476

-25,356

-18,838

-27,938

-19,626

-14,971

-14,653

-12,563

-12,563

-4,622

-2,677